GlassScriptPhysician profile
Catherine Mcquistan
NPI 1619419991
$1,525.61
in general payments reported to CMS, 2019-2025
27 companies · $796 in 2025
The $796 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.73 · 2022: $55.87 · 2023: $75.80 · 2024: $547 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $417.05 | 2024-2025 | |
| Amgen INC. | $146.54 | 2024-2025 | Repatha, Otezla, Repatha |
| Regeneron Healthcare Solutions, INC. | $139.50 | 2025 | Evkeeza |
| Novo Nordisk INC | $87.93 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $71.15 | 2022-2024 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $56.07 | 2023-2025 | Jardiance, Mounjaro |
| Janssen Biotech, INC. | $52.65 | 2021-2023 | Symtuza |
| Bayer Healthcare Pharmaceuticals INC. | $50.20 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.54 | 2023-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $45.42 | 2021-2025 | Gardasil 9, Capvaxive |
| Cleerly, INC. | $42.48 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.77 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $34.50 | 2025 | Purified Cortrophin Gel |
| Viiv Healthcare Company | $32.10 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $31.27 | 2023-2024 | Airsupra, Farxiga |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29.82 | 2024-2025 | |
| Philips North America LLC | $29.07 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Seqirus USA INC | $28.60 | 2025 | Flucelvax, Fluad |
| Gilead Sciences, INC. | $21.47 | 2025 | Biktarvy |
| Mannkind Corporation | $18.38 | 2025 | |
| Tolmar, INC. | $16.77 | 2024 | |
| Antares Pharma, INC. | $15.67 | 2024 | Xyosted |
| Astellas Pharma US INC | $15.06 | 2022 | |
| Radius Health, INC. | $15.05 | 2025 | Tymlos |
| Acella Pharmaceuticals, LLC | $14.45 | 2025 | NP Thyroid 60 |
| Corcept Therapeutics | $13.65 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $13.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Mcquistan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.